IMR Press / FBL / Volume 27 / Issue 9 / DOI: 10.31083/j.fbl2709257
Open Access Review
Combination Therapies against COVID-19
Show Less
1 School of Basic Medical Sciences, Nanchang University, 330047 Nanchang, Jiangxi, China
2 Queen Marry College, Nanchang University, 330047 Nanchang, Jiangxi, China
*Correspondence: (Qunfeng Luo); (Jin Zhang)
Academic Editor: Sang Heui Seo
Front. Biosci. (Landmark Ed) 2022, 27(9), 257;
Submitted: 23 June 2022 | Revised: 14 July 2022 | Accepted: 25 July 2022 | Published: 6 September 2022
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of Coronavirus disease 2019 (COVID-19), which was announced as a pandemic leading to devastating economic and medical burden worldwide. The virus attacks the organ system across the body by binding to its receptor (for example, angiotensin converting enzyme 2) on the surface of the host cell of various organs. The patients present with a variety of pathological symptoms ranging from fever, cough and cytokine storm to acute respiratory distress syndrome (ARDS). Many combination therapies have been developed to combat the disease, via blocking one or more processes of the viral life cycle and/or relieving host complications simultaneously. In this review, the progress of those combination therapies containing at least one small molecule is updated. We believe it’ll provide significant inspiration for further development of treatment strategy against SARS-CoV-2, especially its mutant variants.

combination therapy
31770795/ Thousand Young Talents Program of China, the National Natural Science Foundation of China
81974514/ Thousand Young Talents Program of China, the National Natural Science Foundation of China
20181ACB20014/ Jiangxi Province Natural Science Foundation
Back to top